Generic placeholder image

Current Molecular Medicine

Editor-in-Chief

ISSN (Print): 1566-5240
ISSN (Online): 1875-5666

Mini-Review Article

Dysregulated Long Non-coding RNAs in Myasthenia Gravis-A Mini-Review

Author(s): Liying Sun, Xuhui Ye, Linlin Wang, Junping Yu, Yan Wu, Yun Hua and Lihua Dai*

Volume 25, Issue 1, 2025

Published on: 08 January, 2024

Page: [2 - 12] Pages: 11

DOI: 10.2174/0115665240281531231228051037

Price: $65

conference banner
Abstract

Myasthenia gravis (MG) is an acquired autoimmune disease that is mediated by humoral immunity, supplemented by cellular immunity, along with participation of the complement system. The pathogenesis of MG is complex; although autoimmune dysfunction is clearly implicated, the specific mechanism remains unclear. Long non-coding RNAs (lncRNAs) are a class of non-coding RNA molecules with lengths greater than 200 nucleotides, with increasing evidence of their rich biological functions and high-level structure conservation. LncRNAs can directly interact with proteins and microRNAs to regulate the expression of target genes at the transcription and post-transcription levels. In recent years, emerging studies have suggested that lncRNAs play roles in the differentiation of immune cells, secretion of immune factors, and complement production in the human body. This suggests the involvement of lncRNAs in the occurrence and progression of MG through various mechanisms. In addition, the differentially expressed lncRNAs in peripheral biofluid may be used as a biomarker to diagnose MG and evaluate its prognosis. Moreover, with the development of lncRNA expression regulation technology, it is possible to regulate the differentiation of immune cells and influence the immune response by regulating the expression of lncRNAs, which will provide a potential therapeutic option for MG. Here, we review the research progress on the role of lncRNAs in different pathophysiological events contributing to MG, focusing on specific lncRNAs that may largely contribute to the pathophysiology of MG, which could be used as potential diagnostic biomarkers and therapeutic targets.

Keywords: Long non-coding RNA, myasthenia gravis, pathophysiology, diagnostic biomarkers, therapeutic strategies, autoimmune disease.


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy